Cetuximab Monotherapy Maintenance Treatment in mCRC
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Investigating the efficacy of Cetuximab Monotherapy versus Continuation after induction
treatment with chemotherapy + Cetuximab in inoperable or irresectable and non-progressive
metastatic colorectal cancer after first line induction treatment for 24 weeks with
mFOLFOX6/FOLFIRI and Cetuximab treatment. Reinduction treatment will be done in case of
progression.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Henan Cancer Hospital Jiangsu Cancer Institute & Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University